Highly Sensitive LC-MS/MS Method for Simultaneous and Trace Level Quantification of Ten Nitrosamine Impurities in Olmesartan Medoxomil

Significance of the topic

Regulation of nitrosamine impurities in pharmaceutical products has become critical after genotoxic contaminants were detected in angiotensin II receptor blockers. Trace-level quantification of multiple nitrosamines is essential to ensure patient safety and comply with stringent guidelines from agencies such as the USFDA and EMA.

Objectives and overview of the study

This work aims to develop and validate a rapid, highly sensitive LC-MS/MS method for simultaneous determination of ten nitrosamine impurities in Olmesartan medoxomil, an angiotensin II receptor blocker. The study covers method optimization, performance evaluation, and application to batch analysis.

Methodology and instrumentation

Sample Preparation:

• Weigh 100 mg of Olmesartan drug substance and add 0.25 mL methanol.
• Sonicate for 15 minutes, add 4.75 mL water, sonicate another 30 minutes.
• Centrifuge at 4500 rpm for 15 minutes and filter supernatant through a 0.22 µm PVDF syringe filter.

Chromatographic Conditions:

• Column: InfinityLab Poroshell HPH C18, 4.6×150 mm, 2.7 µm at 40 °C
• Mobile phase A: 0.1% formic acid in water; B: 0.1% formic acid in methanol
• Gradient from 5% to 90% B over 14.5 minutes; flow rate 0.5 mL/min; injection volume 20 µL

MS/MS Conditions:

• Instrument: Agilent 1290 Infinity II UHPLC coupled to 6470 triple quadrupole MS with APCI in positive mode
• Gas temperature 300 °C, gas flow 7 L/min, nebulizer 25 psi, capillary voltage 4000 V, APCI heater 350 °C
• MRM transitions optimized for ten nitrosamines (e.g., NDMA m/z 75→43; CE 16 V; CAV 3 V)

Main results and discussion

The method achieved a lower limit of quantification of 0.1 ng/mL (5 ppb) for all analytes with linearity (R2 > 0.990) over 0.1–10 ng/mL. Seven-point precision studies at 0.6 ng/mL showed %RSD below 7% for peak areas. Recovery for spiked samples ranged from 82% to 110% across two concentration levels. Chromatographic separation of Olmesartan from nitrosamine peaks demonstrated high selectivity and method robustness.

Benefits and practical applications

This high-throughput LC-MS/MS method enables routine monitoring of multiple genotoxic impurities in ARB drug substances. Its sensitivity and reproducibility support regulatory compliance and quality control in pharmaceutical manufacturing.

Future trends and possibilities

Advances may include integration of high-resolution mass spectrometry for broader impurity profiling, miniaturized sample preparation for faster throughput, and application of chemometric tools or machine learning for automated data interpretation. Expansion to other drug classes prone to nitrosamine formation will enhance product safety across the industry.

Conclusion

The developed LC-MS/MS protocol offers a robust, sensitive, and efficient solution for simultaneous trace quantification of ten nitrosamine impurities in Olmesartan medoxomil, aligned with current regulatory requirements and suitable for routine quality assurance workflows.

Reference

1. FDA Liquid Chromatography-High Resolution Mass Spectrometry Method for Six Nitrosamine Impurities in ARB Drugs.
2. FDA Control of Nitrosamine Impurities in Human Drugs Guidance.
3. Agilent Technologies Application Note 5994-1383EN: Determination of Nitrosamine Impurities Using Ultivo Triple Quadrupole LC/MS, 2019.
4. Agilent Technologies Application Note 5994-2286EN: Simultaneous Determination of Eight Nitrosamine Impurities in Metformin Using the 6470 Triple Quadrupole LC/MS, 2020.